Virion Therapeutics LLC
Virion Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel T cell-based immunotherapies for cancer and chronic infectious diseases. Their innovative platform combines genetically encoded checkpoint modifiers with optimized target antigens delivered via viral vectors, aiming to elicit potent, prolonged, and broad CD8+ T cell responses. Their lead product, VRON-0200, is under investigation as a potential functional cure for chronic hepatitis B virus (HBV), with a first-in-human Phase 1b clinical study currently enrolling. Founded in 2018, the company is driven by a mission to revolutionize immunotherapy and has assembled a world-class leadership team with extensive preclinical and clinical expertise.
Industries
Nr. of Employees
small (1-50)
Virion Therapeutics LLC
Newark, Delaware, United States, North America
Products
VRON-0200
A therapeutic vaccine designed to provide a functional cure for chronic hepatitis B virus (HBV) infection by enhancing and broadening CD8+ T cell responses.
VIACT™ Platform
A CD8+ T cell-based immunotherapy platform combining genetically encoded checkpoint modifiers with optimized target antigens delivered via heterologous chimpanzee adenoviral vectors.
VRON-0300
An investigational therapy for advanced solid tumors, currently undergoing IND-enabling studies.
ChiVax™ Technology
A platform using heterologous chimpanzee adenoviral vectors to enhance and broaden T cell responses, particularly in combination with checkpoint modifiers.
VRON-0200
A therapeutic vaccine designed to provide a functional cure for chronic hepatitis B virus (HBV) infection by enhancing and broadening CD8+ T cell responses.
VIACT™ Platform
A CD8+ T cell-based immunotherapy platform combining genetically encoded checkpoint modifiers with optimized target antigens delivered via heterologous chimpanzee adenoviral vectors.
VRON-0300
An investigational therapy for advanced solid tumors, currently undergoing IND-enabling studies.
ChiVax™ Technology
A platform using heterologous chimpanzee adenoviral vectors to enhance and broaden T cell responses, particularly in combination with checkpoint modifiers.